Germany vs Korea: The number of people with susceptibility test result for rifampicin
Germany
83.72
in 2021
Korea
82.06
in 2021
Germany rank
89th
Korea rank
91st
The number of people with susceptibility test result for rifampicin over time
- Germany
- Korea
How they compare
Germany currently reports 83.72 against 82.06 in Korea, a difference of 1.66.
The two have swapped places 2 times across 5 shared years of data; in 2017 it was Germany ahead.
Germany ranks 89th and Korea ranks 91st of 146 countries.
Across the 2 decades both report, Germany averaged higher in 1 and Korea in 1.
Head to head by decade
| Decade | Germany | Korea | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 87.11 | 84.51 | 2.6 | Germany |
| 2020s | 84.9 | 85.46 | 0.5621 | Korea |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher the number of people with susceptibility test result for rifampicin, Germany or Korea?
- Germany, at 83.72 against 82.06 in Korea as of 2021.
- What is the difference in the number of people with susceptibility test result for rifampicin between Germany and Korea?
- 1.66, with Germany ahead.
- How many years of comparable data are there for Germany and Korea?
- 5 years are reported by both, from 2017 to 2021.
- How do Germany and Korea rank globally for the number of people with susceptibility test result for rifampicin?
- Germany ranks 89th and Korea ranks 91st of 146 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.. Statizoid refreshes it automatically from the source and publishes the full history for both places.